Stuttgart
16.01.26 | 21:55
0,004 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln | |||||
| Di | The subscription period in Karolinska Development AB (publ)'s rights issue begins today | 1 | GlobeNewswire (USA) | ||
| Mo | Listing of subscription rights and paid subscription shares of Karolinska Development AB | 87 | GlobeNewswire | With effect from January 13, 2026, the subscription rights of Karolinska Development AB will be traded on the list for Equity rights. Trading will continue up until and including January 22, 2026.
... ► Artikel lesen | |
| 09.01. | Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue | 90 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH... ► Artikel lesen | |
| 08.01. | Karolinska Development AB (publ): Karolinska Development's Extraordinary General Meeting 2026 | 248 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - January 8, 2026. Karolinska Development AB (publ) ("Karolinska Development" or the "Company") held an Extraordinary General Meeting on January 8, 2026, at which the shareholders... ► Artikel lesen | |
| 07.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | 460 | Xetra Newsboard | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| 22.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development | 137 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand... ► Artikel lesen | |
| 11.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D | 147 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia | 149 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a... ► Artikel lesen | |
| 10.12.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01 | 108 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a... ► Artikel lesen | |
| 02.12.25 | Notice of Extraordinary General Meeting in Karolinska Development AB (publ) | 82 | GlobeNewswire (Europe) | The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, ("Karolinska Development" or the "Company") are invited to the Extraordinary General Meeting ("EGM"), on Thursday January... ► Artikel lesen | |
| 01.12.25 | Karolinska Development Launches Rights Issue To Fund Portfolio Growth | 2 | RTTNews | ||
| 01.12.25 | Karolinska Development AB (publ) announces a rights issue of up to approximately SEK 203 million, subject to subsequent approval by the Extraordinary General Meeting, and proposes change of company name to KDventures AB | 126 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH... ► Artikel lesen | |
| 17.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition publishes data on the benefits of early treatment with golexanolone in Parkinson's disease | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | Karolinska Development AB (publ): Interim Report - January-September 2025 | 141 | GlobeNewswire (Europe) | STOCKHOLM - 14 November 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-September 2025. The full report is available on the Company's website. "We... ► Artikel lesen | |
| 04.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia | 167 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate... ► Artikel lesen | |
| 03.11.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company BOOST Pharma raises SEK 34 million through directed share issue to Sound Bioventures | 149 | GlobeNewswire (Europe) | Stockholm, Sweden - November 3, 2025 - Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured... ► Artikel lesen | |
| 31.10.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta | 284 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase... ► Artikel lesen | |
| 28.10.25 | Karolinska Development AB (publ): Karolinska Development invests SEK 7.5 million to support BOOST Pharma's continued development of BT-101 towards Phase 3 | 185 | GlobeNewswire (Europe) | Stockholm, Sweden - October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma's latest... ► Artikel lesen | |
| 24.10.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D | 1 | GlobeNewswire (USA) | ||
| 09.10.25 | Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain | 110 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory authorities... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GSK | 20,980 | -1,59 % | JPMORGAN stuft GSK auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK nach einer Konferenz zum Thema Gesundheit auf "Underweight" mit einem Kursziel von 1700 Pence belassen. Der Pharmakonzern... ► Artikel lesen | |
| BAYER | 41,515 | -1,23 % | Schicksalsjahr 2026: Steht Bayer vor der großen Renaissance? | Lange Zeit glich der Chart der Bayer-Aktie einer schier unendlichen Leidensgeschichte. An der Börse wird jedoch bekanntlich nicht die Gegenwart, sondern die Erwartung an die Zukunft gehandelt. Für Bayer-Aktionäre... ► Artikel lesen | |
| NOVO NORDISK | 53,70 | +0,19 % | Novo Nordisk im Rallyemodus, neue Aufträge für Rheinmetall, DroneShield profitiert von steigenden Rüstungsausgaben und TeamViewer enttäuscht immerhin nicht | Die erste volle Handelswoche im neuen Jahr kann sich aus Anlegersicht sehen lassen. Der DAX schrieb oberhalb von 25.000 Punkten munter Rekorde und die Bullen scheinen noch immer am längeren Hebel zu... ► Artikel lesen | |
| MERCK KGAA | 130,00 | +0,85 % | NurExone Biologic Inc. nimmt an der J.P. Morgan Healthcare Week 2026 teil | ||
| JAGUAR HEALTH | 1,430 | +87,05 % | Jaguar Health, Inc.: Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts | SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday... ► Artikel lesen | |
| HARROW | 47,900 | -1,22 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| PAINREFORM | 1,130 | +37,96 % | PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms | TEL AVIV, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (Nasdaq: PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced its corporate name change to PRF Technologies... ► Artikel lesen | |
| ELI LILLY | 897,20 | +0,18 % | Aktis Oncology: Top-Börsenstart - Eli Lilly profitiert | Am vergangenen Freitag ist der Börsengang des Radiopharma-Spezialisten Aktis Oncology an der Nasdaq über die Bühne gegangen. Die Nachfrage nach den Anteilen der Gesellschaft ging regelrecht durch die... ► Artikel lesen | |
| PFIZER | 22,150 | +0,14 % | Wochenend-Update: Sonntags-Schock: Pfizer - droht Montag der große Abverkauf? | ||
| ASTRAZENECA | 162,25 | +0,34 % | Index-Update: Walmart verdrängt AstraZeneca im Nasdaq 100 | Der US-Einzelhandelsgigant Walmart Inc. steigt in den Nasdaq 100 Index auf und ersetzt dort den Pharmakonzern AstraZeneca. Wie der Indexanbieter Nasdaq am Freitag bekannt gab, werden die Änderungen... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,295 | -1,35 % | Block & Leviton LLP: Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation | Boston, Massachusetts--(Newsfile Corp. - January 13, 2026) - Block & Leviton is investigating Aquestive Therapeutics, Inc. (NASDAQ: AQST) for potential securities law violations. Investors who have... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 88,00 | -2,12 % | Bright Minds Biosciences Inc (2): Bright Minds closes $175-million (U.S.) public offering | ||
| LB PHARMACEUTICALS | 19,970 | -6,59 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ||
| SANOFI | 80,54 | -1,54 % | EU-Kommission genehmigt Sanofi-Medikament zur Verzögerung von Typ-1-Diabetes | Die Europäische Kommission hat dem Pharmakonzern Sanofi die Zulassung für eine neue Therapie zur Verzögerung des Ausbruchs von Typ-1-Diabetes erteilt. Das Medikament Teizeild darf künftig bei Erwachsenen... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 15,140 | -1,75 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report |
Das Unternehmen KAROLINSKA DEVELOPMENT AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,004 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAROLINSKA DEVELOPMENT AB finden Sie auf Wallstreet Online.